Lassen Therapeutics 1 LASN01

Recruitment Target: 8-12 participants

Duration: 18 weeks

Investigational Medicinal Product, Comparator and Randomisation: LASN01 or placebo (approximately 3:1 randomization to active treatment versus placebo).

About the Study

This project is testing the safety, tolerability (if any side effects occur), pharmacokinetics (PK, the amount of study drug in your blood), immunogenicity (if your body makes antibodies against LASN01) and pharmacodynamics (PD, the effect of the study drug on your body) of a single and multiple doses of a new drug called LASN01.

Lassen Therapeutics is developing the study drug LASN01 as a potential new treatment for IPF and PF-ILD. LASN01 is an antibody medication that is directed against a human protein called IL-11 receptor. IL-11 receptor is believed to be the starting point of the complex cellular process that eventually leads to the fibrosis in the lung. By blocking the IL- 11 receptor, it is believed that LASN01 can prevent the progress of and alleviate PF- ILD symptoms.

Can I Participate?

If you would like to take part or have any questions about this research study, please fill out our “Research Enquiry” form or contact the PACT Trial Information Officer, Naomi Derrick via naomi.derrick@sydney.edu.au.

Clinicaltrials.gov ID: NCT05331300